Literature DB >> 9646986

Malignancy metastatic to the pleura.

S A Sahn1.   

Abstract

Malignancy is one of the most common causes of exudative effusions and increases in incidence in the elderly. Lung cancer is the most common cause of malignant effusion caused by contiguous spread and its propensity to invade the pulmonary vasculature and embolize to the visceral pleura. Lung, breast, ovary, and gastric cancer and lymphomas account for about 80% of all malignant effusions. Dyspnea and cough are the most common symptoms at presentation. Thirty percent of patients have a low pleural fluid pH (> or = 7.30) and glucose (> 60 mg/dL) at presentation, which predicts a decreased survival, an increase yield on diagnostic studies, and a poor response to chemical pleurodesis. Talc by poudrage or slurry is the most successful pleurodesis agent. Pleural peritoneal shunt is an option for patients with an intractable, symptomatic malignant effusion who cannot undergo or who have failed pleurodesis.

Entities:  

Mesh:

Year:  1998        PMID: 9646986     DOI: 10.1016/s0272-5231(05)70082-4

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  14 in total

Review 1.  Video-assisted thoracic surgery--the past, present status and the future.

Authors:  Shi-ping Luh; Hui-ping Liu
Journal:  J Zhejiang Univ Sci B       Date:  2006-02       Impact factor: 3.066

Review 2.  Malignant pleural effusions: appropriate treatment approaches.

Authors:  Yener Aydin; Atila Turkyilmaz; Yavuz Selim Intepe; Atilla Eroglu
Journal:  Eurasian J Med       Date:  2009-12

3.  Predictive models of malignant transudative pleural effusions.

Authors:  Lucía Ferreiro; Francisco Gude; María E Toubes; Adriana Lama; Juan Suárez-Antelo; Esther San-José; Francisco Javier González-Barcala; Antonio Golpe; José M Álvarez-Dobaño; Carlos Rábade; Nuria Rodríguez-Núñez; Carla Díaz-Louzao; Luis Valdés
Journal:  J Thorac Dis       Date:  2017-01       Impact factor: 2.895

4.  Cytologic features of a pleural effusion after silicone breast implant rupture.

Authors:  José A Jiménez-Heffernan; Alejandra Rosell; Emma Vázquez-Espinosa; Carmen Idoate-Ortueta; Marta Solís-García; Eduardo Pacios
Journal:  Virchows Arch       Date:  2022-10-13       Impact factor: 4.535

5.  Pleural fluid analysis of lung cancer vs benign inflammatory disease patients.

Authors:  R Kremer; L A Best; D Savulescu; M Gavish; R M Nagler
Journal:  Br J Cancer       Date:  2010-03-09       Impact factor: 7.640

6.  Reactive oxygen metabolites can be used to differentiate malignant and non-malignant pleural efffusions.

Authors:  Ufuk Cobanoglu; Fuat Sayir; Duygu Mergan
Journal:  Ann Thorac Med       Date:  2010-07       Impact factor: 2.219

7.  Pleurodesis in patients with malignant pleural effusions: talc slurry or bleomycin? Results of a prospective randomized trial.

Authors:  Fabio José Haddad; Riad Naim Younes; Jefferson Luiz Gross; Daniel Deheinzelin
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

8.  Lymphangitic carcinomatosis as a cause of malignant transient pleural transudate.

Authors:  Raquel Garcia Sevila; Encarnacion Barroso; Concepcion Martin; Ignacio Aranda; Santiago Romero
Journal:  Case Rep Med       Date:  2009-09-08

Review 9.  Surgical and other invasive approaches to recurrent pleural effusion with malignant etiology.

Authors:  Siyamek Neragi-Miandoab
Journal:  Support Care Cancer       Date:  2008-02-08       Impact factor: 3.603

10.  What is the clinical significance of transudative malignant pleural effusion?

Authors:  Jeong-Seon Ryu; Seong-Tae Ryu; Young-Shin Kim; Jae-Hwa Cho; Hong-Lyeol Lee
Journal:  Korean J Intern Med       Date:  2003-12       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.